ClinicalTrials.gg
WithdrawnNCT07039422VAY RE-HITUpdated Oct 15, 2026

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

A Phase 2 interventional study of Ianalumab in Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
Updated Oct 15, 2026Now WithdrawnNo longer in 14 countries+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Enrollment
12th of 12
0 · median 39
Started
2026
with 2 others
Phase 2
7 of 17
2 open now
Registered
11th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).

Read the detailed description

This is a multicenter, Phase 2 exploratory study to assess the efficacy and safety of a second course of ianalumab in adults with ITP and wAIHA who have previously benefited from ianalumab.

All participants will receive ianalumab at the dose of study treatment from which they previously derived benefit.

After completion of the screening period, participants who do not meet treatment failure criteria during treatment period will enter the safety and efficacy follow-up, whereas participants who reported a treatment failure during the treatment period will enter the safety follow-up only.

The study will end once all participants have completed safety and/or efficacy follow-up since their last dose of ianalumab or discontinued the study earlier.

03

Conditions studied

  • Primary Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia

Keywords

  • Primary Immune Thrombocytopenia (ITP)
  • ITP
  • Warm Autoimmune Hemolytic Anemia (wAIHA)
  • wAIHA
  • VAY736
  • Ianalumab
  • B-cell depletion
  • B-cell Activating Factor Receptor (BAFF-R) blockade
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed obtained prior to participation in the study.
  • Male or female participants aged 18 years and older on the day of signing informed consent

Primary ITP patients:

  • Previously enrolled and treated either with ianalumab/placebo in addition to on protocol CVAY736I12301 or with ianalumab/placebo in addition to eltrombopag in the second line on protocol CVAY736Q12301, and who experienced treatment failure (TF) by parent trial definition ≥ 2 years after the last infusion of ianalumab/placebo
  • Rescue medication and/or bridging therapy are allowed to be started within the 28 days prior to screening; count results obtained prior to the start of the therapy must be used to assess eligibility and have to be collected within 30 days prior to screening

For Primary or Secondary wAIHA patients:

  • Previously documented by a positive direct antiglobulin test (DAT) specific for anti-IgG or anti-IgA, previously enrolled and treated with ianalumab/placebo in blinded cohort or placebo followed by crossover to open label ianalumab in protocol CVAY736O12301, having experienced durable response lasting beyond 2 years from the last infusion of ianalumab/placebo in blinded cohorts or a durable response beyond week 20 from last dose of first course of ianalumab in the crossover arm.
  • wAIHA with concentration ≥5 g/dL and \<10 g/dL and presence of symptoms related to anemia during screening or within 14 days before screening window or within 28 days before screening window if rescue medication/bridging therapy has been initiated.
  • Rescue medication and/or bridging therapy are allowed to be started during the screening and within 28 days prior to screening; hemoglobin level result for eligibility assessment needs to be obtained prior to the start of the treatment within 30 days prior to screening
  • Supportive care is allowed in the case the participant received it in the parent trial when the relapse occurred and has remained stable at least 4 weeks prior screening

Exclusion criteria

Exclusion Criteria:

  • Evans syndrome or any cytopenia other than thrombocytopenia (for ITP participants) or anemia (for wAIHA), except for grade 1 anemia due to blood loss or iron deficiency.
  • Secondary wAIHA with BM involvement for wAIHA patients
  • Current life-threatening bleeding or history of life-threatening bleeding due to thrombocytopenia
  • Therapy for ITP or wAIHA other than ianalumab/placebo, bridging/rescue therapies and supportive care prior to the beginning of the screening window
  • After primary analysis of each respective parent trial, participants whose treatment was unblinded and who received placebo only will be excluded.
  • ITP participants only: Participants with concurrent coagulation disorders and/or receiving anti- or anti-coagulant medication except for low dose of acetylsalicylic acid (≤150 mg per day)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment arm 1

    Participants will receive ianalumab lower dose

    Biological: Ianalumab

  • Experimental
    Treatment arm 2

    Participants will receive ianalumab higher dose

    Biological: Ianalumab

Interventions

  • BiologicalIanalumab

    Concentrate for solution for infusion for intravenous use

    Also known as: VAY736

06

What researchers measure

Primary outcomes

  1. Treatment failure free (yes, no) for participants with Immune Thrombocytopenia (ITP)

    Treatment failure free (yes, no) by 12 months after start of second course of ianalumab at assigned dose.

    Time frame: From treatment start date until the events indicative of treatment failure (up to 2 years after last dose)

  2. Durable response for participants with Warm Autoimmune Hemolytic Anemia (wAIHA)

    Durable response (hemoglobin (Hb) ≥10 g/dL and ≥2 g/dL increase from baseline) for a period of at least 8 consecutive weeks, between W9 and W25 in the absence of rescue or prohibited treatment prior to that durable response achievement.

    Time frame: At least 8 consecutive weeks, between week 9 and week 25

Secondary outcomes

  1. Response rate in participants with ITP only

    Percentage of participants with ITP achieving a response among all participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  2. Complete response rate in participants with ITP only

    Percentage of participants with ITP achieving a complete response among all participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  3. Number and percentage of participants receiving new ITP therapy only

    Number and percentage of participants who need new ITP therapy among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  4. Response and complete response in participants with wAIHA only

    Percentage of participants with wAIHA achieving a response and complete response among all participants who received a second course of ianalumab and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  5. Number and percentage of participants receiving new wAIHA therapy only

    Number and percentage of participants who need new wAIHA therapy among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  6. Number and percentage of participants receiving rescue treatment

    Number and percentage of participants who need rescue treatment among all the participants who received a second course of ianalumab, and among cohorts and/or group of cohorts.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  7. Number of severe infections and percentage of participants with severe infection

    This is to assess the safety profile of ianalumab.

    Time frame: from treatment start to end of study (up to 2 years after last dose)

  8. Ianalumab concentration in serum

    Assess the pharmacokinetics of a second course of ianalumab treatment.

    Time frame: after first dose (pre dose 0 and 672 hours) and at study end (up to 2 years after last dose of Ianalumab)

  9. Incidence of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of Ianalumab.

    Time frame: up to end of treatment (Week 16), end of study (up to 2 years after last dose of Ianalumab)

  10. Titer of anti-ianalumab antibodies in serum (ADA assay) over time

    Assess the immunogenicity of second course of ianalumab treatment.

    Time frame: up to end of treatment (Week 16), end of study (up to 2 years after last dose of Ianalumab)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Aug 2030, 50 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Jun 26, 2025
StartEst.
Jun 26, 2026
Primary completionEst.
Aug 30, 2030
CompletionEst.
Aug 30, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
changed Oct 15, 2026
Sites
25 sites removed; no longer in Argentina, Belgium, China, Czechia, France and 9 more
All 14 countries

Argentina, Belgium, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Romania, Singapore, Spain, Turkey (Türkiye), United Kingdom

Show 25 removed
  • Novartis Investigative Site · Buenos Aires, Argentina
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · Guangzhou, China
  • Novartis Investigative Site · Dalian, China
  • Novartis Investigative Site · Tianjin, China
  • Novartis Investigative Site · Ostrava, Czechia
  • Novartis Investigative Site · Caen, France
  • Novartis Investigative Site · Rennes, France
  • Novartis Investigative Site · Jena, Germany
  • Novartis Investigative Site · Debrecen, Hungary
  • Novartis Investigative Site · Florence, Italy
  • Novartis Investigative Site · Roma, Italy
  • Novartis Investigative Site · Trieste, Italy
  • Novartis Investigative Site · Vicenza, Italy
  • Novartis Investigative Site · George Town, Malaysia
  • Novartis Investigative Site · Johor Bahru, Malaysia
  • Novartis Investigative Site · Kuala Selangor, Malaysia
  • Novartis Investigative Site · Bucharest, Romania
  • Novartis Investigative Site · Singapore, Singapore
  • Novartis Investigative Site · Barcelona, Spain
  • Novartis Investigative Site · Madrid, Spain
  • Novartis Investigative Site · Murcia, Spain
  • Novartis Investigative Site · Samsun, Turkey (Türkiye)
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
  • Novartis Investigative Site · London, United Kingdom
Oct 15, 2026
Enrollment
60 (estimated)→0 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Withdrawn
    Why stopped The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.
    25 sites removed; no longer in Argentina, Belgium, China, Czechia, France and 9 more
    All 14 countries

    Argentina, Belgium, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Romania, Singapore, Spain, Turkey (Türkiye), United Kingdom

    Show 25 removed
    • Novartis Investigative Site · Buenos Aires, Argentina
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · Guangzhou, China
    • Novartis Investigative Site · Dalian, China
    • Novartis Investigative Site · Tianjin, China
    • Novartis Investigative Site · Ostrava, Czechia
    • Novartis Investigative Site · Caen, France
    • Novartis Investigative Site · Rennes, France
    • Novartis Investigative Site · Jena, Germany
    • Novartis Investigative Site · Debrecen, Hungary
    • Novartis Investigative Site · Florence, Italy
    • Novartis Investigative Site · Roma, Italy
    • Novartis Investigative Site · Trieste, Italy
    • Novartis Investigative Site · Vicenza, Italy
    • Novartis Investigative Site · George Town, Malaysia
    • Novartis Investigative Site · Johor Bahru, Malaysia
    • Novartis Investigative Site · Kuala Selangor, Malaysia
    • Novartis Investigative Site · Bucharest, Romania
    • Novartis Investigative Site · Singapore, Singapore
    • Novartis Investigative Site · Barcelona, Spain
    • Novartis Investigative Site · Madrid, Spain
    • Novartis Investigative Site · Murcia, Spain
    • Novartis Investigative Site · Samsun, Turkey (Türkiye)
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    • Novartis Investigative Site · London, United Kingdom
    Enrollment 60 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07039422
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jun 26, 2026 (estimated)
Primary completion
Aug 30, 2030 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion